Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes

Authors: Li Sheng, Wenjie Cao, Bingbing Cha, Zhaoping Chen, Fang Wang, Jun Liu

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Objective

To investigate the association of serum osteocalcin with carotid atherosclerosis in patients with type 2 diabetes.

Methods

We performed a cross-sectional community-based study in metropolitan area. Serum total osteocalcin was measured by radioimmunoassay in 382 men and 435 postmenopausal women. The carotid artery intima-media thickness (IMT) and carotid plaques (PLQ) were measured by B-mode ultrasound.

Results

The crude mean of serum osteocalcin concentrations were 4.52±2.43 ng/ml for men and 5.75±2.92 ng/ml for postmenopausal women (P <0.001), respectively. Osteocalcin levels were associated inversely with age, fasting serum insulin, HOMA-IR, ALT, triglycerides, total cholesterol, LDL- cholesterol, CRP (all P<0.001) and positively with adiponectin and HOMA-B (all P<0.05). After multiple adjustment, the odds ratios (ORs) were substantially higher risk for carotid plaques (OR 1.77 for 1 SD decrease in osteocalcin, 95% CI 1.23-2.76, p=0.005). These associations remained significant after further adjustment for potential confounder.

Conclusions

Serum osteocalcin levels is an independent risk factor for carotid atherosclerosis in patients with type 2 diabetes.
Literature
1.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997, 96: 1432-1437. 10.1161/01.CIR.96.5.1432.CrossRefPubMed
2.
O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Jr Wolfson SK: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999, 340: 14-22. 10.1056/NEJM199901073400103.CrossRefPubMed
3.
Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S: Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism. 2002, 51: 244-247. 10.1053/meta.2002.28971.CrossRefPubMed
4.
Melidonis A, Kyriazis IA, Georgopali A, Zairis M, Lyras A, Lambropoulos T, Matsaidonis D, Foussas S: Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients. Diabetes Care. 2003, 26: 3189-3190. 10.2337/diacare.26.11.3189.CrossRefPubMed
5.
Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M: Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke. 1996, 27: 1986-1992. 10.1161/01.STR.27.11.1986.CrossRefPubMed
6.
Goff DC, D'Agostino RB, Haffner SM, Saad MF, Wagenknecht LE: Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2000, 23: 1006-1011. 10.2337/diacare.23.7.1006.CrossRefPubMed
7.
Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G: Insulin signalling in osteoblasts integrates bone remodelling and energy metabolism. Cell. 2010, 142: 296-308. 10.1016/j.cell.2010.06.003.PubMedCentralCrossRefPubMed
8.
9.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000, 100: 197-207. 10.1016/S0092-8674(00)81558-5.CrossRefPubMed
10.
Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005, 434: 514-520. 10.1038/nature03398.CrossRefPubMed
11.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G: Endocrine regulation of energy metabolism by the skeleton. Cell. 2007, 130: 456-469. 10.1016/j.cell.2007.05.047.PubMedCentralCrossRefPubMed
12.
Ferron M, Hinoi E, Karsenty G, Ducy P: Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008, 105: 5266-5270. 10.1073/pnas.0711119105.PubMedCentralCrossRefPubMed
13.
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T: Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009, 94: 45-49.CrossRefPubMed
14.
Chen L, Li Q, Yang Z, Ye Z, Huang Y, He M, Wen J, Wang X, Lu B, Hu J, Liu C, Ling C, Qu S, Hu R: Osteocalcin, glucose metabolism, lipid profile and chronic low-grade inflammation in middle-aged and elderly Chinese. Diabet Med. 2012, 10.1111/j.1464-5491.2012.03769.x.
15.
Bao Y, Zhou M, Lu Z, Li H, Wang Y, Sun L, Gao M, Wei M, Jia W: Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. Clin Endocrinol (Oxf). 2011, 75: 196-201. 10.1111/j.1365-2265.2011.04065.x.CrossRef
16.
D'Agostino RB, Burke G, O'Leary D, Rewers M, Selby J, Savage PJ, Saad MF, Bergman RN, Howard G, Wagenknecht L, Haffner SM: Ethnic differences in carotid wall thickness. The Insulin Resistance Atherosclerosis Study. Stroke. 1996, 27: 1744-9. 10.1161/01.STR.27.10.1744.CrossRefPubMed
17.
Wei M, Gonzalez C, Haffner SM, O'Leary DH, Stern MP: Ultrasonographically assessed maximum carotid artery wall thickness in Mexico City residents and Mexican Americans living in San Antonio, Texas. Association with diabetes and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1996, 16: 1388-92. 10.1161/01.ATV.16.11.1388.CrossRefPubMed
18.
Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, Zhang Z, Qu S, Hu R: Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 72-10.1186/1475-2840-10-72.PubMedCentralCrossRefPubMed
19.
Chen L, Yang Z, Lu B, Li Q, Ye Z, He M, Huang Y, Wang X, Zhang Z, Wen J, Liu C, Qu S, Hu R: Serum CXC ligand 5 is a new marker of subclinical atherosclerosis in type 2 diabetes. Clin Endocrinol (Oxf). 2011, 75: 766-70. 10.1111/j.1365-2265.2011.04119.x.CrossRef
20.
Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Hankey GJ, Beilby JP, Norman PE: Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. Osteoporos Int. 2012, 23: 599-606. 10.1007/s00198-011-1586-1.CrossRefPubMed
21.
Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M, Arcaro G: Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf). 2006, 65: 593-7. 10.1111/j.1365-2265.2006.02633.x.CrossRef
22.
Bzowska M, Nogieć A, Skrzeczyńska-Moncznik J, Mickowska B, Guzik K, Pryjma J: Oxidized LDLs inhibit TLR-induced IL-10 production by monocytes: a new aspect of pathogen-accelerated atherosclerosis. Inflammation. 2012, 35: 1567-84. 10.1007/s10753-012-9472-3.PubMedCentralCrossRefPubMed
23.
Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R: Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep. 2011, 38: 1145-50. 10.1007/s11033-010-0212-1.CrossRefPubMed
24.
Yang Z, Zhang Z, Wen J, Wang X, Lu B, Yang Z, Zhang W, Wang M, Feng X, Ling C, Wu S, Hu R: Elevated serum chemokine CXC ligand 5 levels are associated with hypercholesterolemia but not a worsening of insulin resistance in Chinese people. J Clin Endocrinol Metab. 2010, 95: 3926-32. 10.1210/jc.2009-2194.CrossRefPubMed
25.
Fadini GP, Albiero M, Menegazzo L, Boscaro E, Agostini C, de Kreutzenberg SV, Rattazzi M, Avogaro A: Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res. 2012, 2012: 921685.PubMedCentralPubMed
26.
Fadini GP, Albiero M, Menegazzo L, Boscaro E, Vigili De Kreutzenberg S, Agostini C, Cabrelle A, Binotto G, Rattazzi M, Bertacco E, Bertorelle R, Biasini L, Mion M, Plebani M, Ceolotto G, Angelini A, Castellani C, Menegolo M, Grego F, Dimmeler S, Seeger F, Zeiher A, Tiengo A, Avogaro A: Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res. 2011, 108: 1112-21. 10.1161/CIRCRESAHA.110.234088.CrossRefPubMed
27.
Muneyuki T, Nakajima K, Aoki A, Yoshida M, Fuchigami H, Munakata H, Ishikawa SE, Sugawara H, Kawakami M, Momomura S, Kakei M: Latent associations of low serum amylase with decreased plasma insulin levels and insulin resistance in asymptomatic middle-aged adults. Cardiovasc Diabetol. 2012, 11: 80-10.1186/1475-2840-11-80.PubMedCentralCrossRefPubMed
28.
Reyes-Garcia R, Rozas-Moreno P, Jimenez-Moleon JJ, Villoslada MJ, Garcia-Salcedo JA, Santana-Morales S, Muñoz-Torres M: Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. Diabetes Metab. 2012, 38: 76-81. 10.1016/j.diabet.2011.07.008.CrossRefPubMed
29.
Håglin L, Bäckman L, Törnkvist B: A structural equation model for assessment of links between changes in serum triglycerides, -urate, and -glucose and changes in serum calcium, -magnesium and -phosphate in type 2 diabetes and non-diabetes metabolism. Cardiovasc Diabetol. 2011, 10: 116-10.1186/1475-2840-10-116.PubMedCentralCrossRefPubMed
30.
Kanazawa I, Yamaguchi T, Sugimoto T: Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011, 92: 393-9. 10.1016/j.diabres.2011.03.015.CrossRefPubMed
31.
Reinhard H, Nybo M, Hansen PR, Wiinberg N, Kjær A, Petersen CL, Winther K, Parving HH, Rasmussen LM, Rossing P, Jacobsen PK: Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. Cardiovasc Diabetol. 2011, 10: 70-10.1186/1475-2840-10-70.PubMedCentralCrossRefPubMed
32.
Pennisi P, Russo E, Gaudio A, Veca R, D'Amico F, Mangiafico RA, Laspina M, Tringali G, Signorelli SS, Fiore CE: The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role?. Maturitas. 2010, 67: 358-62. 10.1016/j.maturitas.2010.07.013.CrossRefPubMed
33.
Criqui MH, Kamineni A, Allison MA, Ix JH, Carr JJ, Cushman M, Detrano R, Post W, Wong ND: Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010, 30: 2289-96. 10.1161/ATVBAHA.110.208181.PubMedCentralCrossRefPubMed
34.
Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001, 21: 1998-2003. 10.1161/hq1201.100229.CrossRefPubMed
35.
Ichijima T, Matsuzaka K, Tonogi M, Yamane GY, Inoue T: Osteogenic differences in cultured rat periosteal cells under hypoxic and normal conditions. Exp Ther Med. 2012, 3: 165-170. 10.3892/etm.2011.393.PubMedCentralPubMed
Metadata
Title
Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes
Authors
Li Sheng
Wenjie Cao
Bingbing Cha
Zhaoping Chen
Fang Wang
Jun Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-22

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Original investigation

Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC

Original investigation

Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women

Original investigation

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes

Original investigation

Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus

Original investigation

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns

Original investigation

Impaired skin microcirculation in paediatric patients with type 1 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits